Reducing Disease Risk and Extending Life: Rethinking the Role of Menopausal Hormone Therapy

Friday, October 27, 2017
The Anlyan Center
300 Cedar Street
New Haven, CT
effects of ET, but went largely unnoticed. Despite these positive findings, use of ET after hysterectomy steeply declined from more than 90% to less than 50% due to cardiovascular disease, have been attributed to non-use of ET after hysterectomy, with and without oophorectomy experienced by women who have had a hysterectomy, with and without oophorectomy.

Conclusions

Although extensive information is available supporting the role of estrogens for primary care prevention of cardiovascular and other diseases in women after hysterectomy, this information is not widely known or appreciated by either healthcare professionals or women themselves. The first report of the Women’s Health Initiative (WHI) estrogen plus progestogen findings in 2002 led to fear of all menopause hormone therapies. The 2004 WHI estrogen only (ET) findings in women who had a hysterectomy reported major benefits and minimal adverse effects of ET, but went largely unnoticed. Despite these positive findings, use of ET after hysterectomy steeply declined from more than 90% to less than 50% due to cardiovascular disease, have been attributed to non-use of ET after hysterectomy. This Symposium aims to increase knowledge about the risks of untreated estrogen deficiency and about the efficacy and safety of ET. We hope this increased knowledge will lead more healthcare professionals to recognize estrogen deficiency and about the efficacy and safety of ET. We hope this increased knowledge will lead more healthcare professionals to recognize estrogen deficiency and about the efficacy and safety of ET.

Conference Schedule

7:30 AM Registration and Continental Breakfast
8:30 AM Welcome and Introductory Remarks
Lawrence S. Cohen MD, FACC
9:30 AM Protecting Your Patient’s Heart
Jeffrey R. Bender MD
10:00 AM Assessment of Hormone Therapy: Update
Philip M. Sarrel MD
11:00 AM Panel Discussion: Challenges to Care
Jeffrey R. Bender MD; Lee S. Cohen MD; Mary Jane Minkin MD; Philip M. Sarrel MD; and Hugh S. Taylor MD
1:00 PM Closing Remarks and Adjournment

Learning Objectives

Participants in this course will be able to describe:

1. The increased risk of cardiovascular disease, unusual symptoms, and increased mortality experienced by women who have had a hysterectomy, with and without oophorectomy.
2. The increased risk for mood disorders related to surgical and natural menopause and the effectiveness of hormone therapy for treating these symptoms.
3. The importance of early intervention with estrogens for controlling symptoms and for the primary prevention of cardiovascular disease in women.
4. Recent assessments of estrogen therapy in support of its use for the prevention of cardiovascular disease, reducing the risk for developing breast cancer, and lowering mortality rates.
5. An approach to evaluation and treatment of menopausal patients in their practices.
6. Challenges and solutions to improving menopause health care.

Online Registration

Registration fee* includes all conference materials, continental breakfast, and refreshment break.

Physicians - $125
Nurses/PAs/Allied Health Professionals - $75
Non-Yale Residents/Fellows/Students* – $50
Yale Residents/Fellows/Students – complimentary, ID required at registration desk.

Registration must be completed online. Please see above Online Instructions to complete the registration process.

If you have any questions, please contact Yale CME at cme@yale.edu or 203.785.4578.

*Registration must be completed online. Please see above Online Instructions to complete the registration process.

Registration Information

PLEASE NOTE: You must register online. This informational panel is not a registration form.

Reducing Disease Risk and Extending Life: Rethinking the Role of Menopausal Hormone Therapy

Friday, October 27, 2017

Register online, at cme.yale.edu

Online Registration Instructions:

1. Click “Our Offerings”
2. Go to “Live Courses”
3. Scroll down and select “Reducing Disease Risk and Extending Life: Rethinking the Role of Menopausal Hormone Therapy”
4. Click the “Register” link in order to proceed

Please note: You will be required to login or create a profile to register.

OR, Please scan the image at right (QR Code) with your Smartphone or Tablet to be directed to the conference homepage and proceed with Step 4.

Registration Fees

Physicians - $125
Nurses/PAs/Allied Health Professionals - $75
Non-Yale Residents/Fellows/Students* – $50
Yale Residents/Fellows/Students – complimentary, ID required at registration desk.

*Registration must be completed online. Please see above Online Instructions to complete the registration process.

Center for Continuing Medical Education
Yale School of Medicine
333 Cedar Street
P.O. Box 208052
New Haven, CT 06520-8052

Registration must be completed online.

If you have any questions, please contact Yale CME at cme@yale.edu or 203.785.4578.
after hysterectomy steeply declined due to cardiovascular disease, have been attributed to non-use of ET after hysterectomy.

The first report of the Women's Health Initiative (WHI) estrogen plus progestogen findings in 2002 led to fear of all menopause hormone therapies. The 2004 WHI estrogen only (ET) findings in women who had a hysterectomy reported major benefits and minimal adverse effects only (ET) findings in women who had a hysterectomy reported major benefits and minimal adverse effects.

Not using ET has left millions of women after hysterectomy reported major benefits and minimal adverse effects.

The WHI estrogen plus progestogen findings in 2002 led to fear of all menopause hormone therapies. The 2004 WHI estrogen only (ET) findings in women who had a hysterectomy reported major benefits and minimal adverse effects. The 2004 WHI estrogen plus progestogen findings in 2002 led to fear of all menopause hormone therapies.

The first report of the Women's Health Initiative (WHI) estrogen plus progestogen findings in 2002 led to fear of all menopause hormone therapies.

Although extensive information is available supporting the role of estrogens for primary care prevention of cardiovascular and other diseases in women after hysterectomy, this information is not widely known or appreciated by either healthcare professionals or women themselves. The first report of the Women's Health Initiative (WHI) estrogen plus progestogen findings in 2002 led to fear of all menopause hormone therapies.

The first report of the Women's Health Initiative (WHI) estrogen plus progestogen findings in 2002 led to fear of all menopause hormone therapies.

The WHI estrogen plus progestogen findings in 2002 led to fear of all menopause hormone therapies.

This Symposium aims to increase knowledge about the risks of untreated estrogen deficiency and the about the efficacy of ET. This Symposium aims to increase knowledge about the risks of untreated estrogen deficiency and the about the efficacy of ET. This Symposium aims to increase knowledge about the risks of untreated estrogen deficiency and the about the efficacy of ET.

Challenges and solutions to improving menopause health care

Recent assessments of estrogen therapy in support of its use for the prevention of cardiovascular disease in women.

The increased risk of cardiovascular disease, unusual symptoms, and increased mortality experienced by women who have had a hysterectomy, with and without oophorectomy.

The increased risk for mood disorders related to surgical and natural menopause and the effectiveness of hormone therapy for treating these symptoms.

The increased risk of cardiovascular disease, unusual symptoms, and increased mortality experienced by women who have had a hysterectomy, with and without oophorectomy.

The importance of early intervention with estrogens for controlling symptoms and for the primary prevention of cardiovascular disease in women.

Recent assessments of estrogen therapy in support of its use for the prevention of cardiovascular disease, reducing the risk for developing breast cancer, and lowering mortality rates.

An approach to evaluation and treatment of menopausal patients in their practices.

Challenges and solutions to improving menopause health care.

Impact on Healthcare Professionals Knowledge and Patient Care

Although extensive information is available supporting the role of estrogens for primary care prevention of cardiovascular and other diseases in women after hysterectomy, this information is not widely known or appreciated by either healthcare professionals or women themselves. The first report of the Women's Health Initiative (WHI) estrogen plus progestogen findings in 2002 led to fear of all menopause hormone therapies.

The WHI estrogen plus progestogen findings in 2002 led to fear of all menopause hormone therapies.

The increased risk of cardiovascular disease, unusual symptoms, and increased mortality experienced by women who have had a hysterectomy, with and without oophorectomy.

The increased risk of cardiovascular disease, unusual symptoms, and increased mortality experienced by women who have had a hysterectomy, with and without oophorectomy.

The importance of early intervention with estrogens for controlling symptoms and for the primary prevention of cardiovascular disease in women.

Recent assessments of estrogen therapy in support of its use for the prevention of cardiovascular disease, reducing the risk for developing breast cancer, and lowering mortality rates.

An approach to evaluation and treatment of menopausal patients in their practices.

Challenges and solutions to improving menopause health care.

Learning Objectives

Participants in this course will be able to describe:

- The increased risk of cardiovascular disease, unusual symptoms, and increased mortality experienced by women who have had a hysterectomy, with and without oophorectomy.

- The increased risk for mood disorders related to surgical and natural menopause and the effectiveness of hormone therapy for treating these symptoms.

- The importance of early intervention with estrogens for controlling symptoms and for the primary prevention of cardiovascular disease in women.

- Recent assessments of estrogen therapy in support of its use for the prevention of cardiovascular disease, reducing the risk for developing breast cancer, and lowering mortality rates.

- An approach to evaluation and treatment of menopausal patients in their practices.

- Challenges and solutions to improving menopause health care.

Conference Schedule

This conference is being held at The Ahmanson Center for Medical Research and Education, 1st Floor Auditorium, 300 Cedar Street, New Haven, CT.

7:30 AM Registration and Continental Breakfast

8:30 AM Welcome and Introductory Remarks

Lawrence S. Cohen MD, FACC

Michelle Robrun (special guest: “A Woman’s Voice”)

9:00 AM Assessment of Hormone Therapy: Update

Philip M. Sarrel MD

10:00 AM Mood Disorders and Estrrogen Therapy

Lee S. Cohen MD

11:00 AM Protecting Your Patient’s Heart

Jeffrey R. Bender MD

11:30 AM Panel Discussion: Challenges to Care

Jeffrey R. Bender MD; Lee S. Cohen MD; Mary Jane Minkin MD; Philip M. Sarrel MD; and Hugh S. Taylor MD

12:30 PM Closing Remarks and Adjourn

Registration Information

PLEASE NOTE: You must register online. This informational panel is not a registration form.

Reducing Disease Risk and Extending Life: Rethinking the Role of Menopausal Hormone Therapy

Friday, October 27, 2017

Register online, at cme.yale.edu

ONLINE REGISTRATION INSTRUCTIONS:

1. Go to “Our Offerings”
2. Go to “Live Courses”
3. Scroll down and select “Reducing Disease Risk and Extending Life: Rethinking the Role of Menopausal Hormone Therapy”
4. Click the “Register” link in order to proceed

Please note: You will be required to login or create a profile to register

GREAT NEWS: You can use your Smartphone or Tablet to be directed to the conference homepage and proceed with Step 4.

OR, Please scan the image at right (QR Code) with your Smartphone or Tablet to be directed to the conference homepage and proceed with Step 4.

REGISTRATION FEES

Registration fee* includes all conference materials, continental breakfast, and refreshment break.

Physicians - $125

Nurses/PAs/Allied Health Professionals - $75

Non-Yale Residents/Fellows/Students† - $50

Yale Residents/Fellows/Students - complimentary, ID required at registration desk

★ Registration must be completed online. Please see above Online Instructions to complete the registration process.

All cancellations must be received in writing (or via e-mail) at least one week prior to the start of the conference to receive a refund. Any requests for refunds received after this date, or by telephone, will not be honored.

A letter of verification from department head must accompany registration. Letter should be sent separately to Yale-CME at the above address. You may also e-mail a pdf copy of your verification letter to cme@yale.edu.

If you have any questions, please contact Yale CME at cme@yale.edu or 203.785.4578.
Reducing Disease Risk and Extending Life: Rethinking the Role of Menopausal Hormone Therapy

Friday, October 27, 2017
The Anlyan Center
300 Cedar Street
New Haven, CT